Patents by Inventor Patrick Sieber

Patrick Sieber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NADPH OXIDASE 4 INHIBITORS
    Publication number: 20210395238
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Application
    Filed: September 3, 2021
    Publication date: December 23, 2021
    Applicant: ACTELTION PHARMACEUTICALS LTD
    Inventors: Hamed AISSAOUI, Martin BOLLI, Christoph BOSS, Sylvia RICHARD-BILDSTEIN, Patrick SIEBER
  • NADPH oxidase 4 inhibitors
    Patent number: 11136317
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: October 5, 2021
    Assignee: Actelion Pharmaceuticals LTD
    Inventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
  • NADPH OXIDASE 4 INHIBITORS
    Publication number: 20200165235
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
  • NADPH oxidase 4 inhibitors
    Patent number: 10584118
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: March 10, 2020
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
  • Evaluation of the positioning of an examination object
    Patent number: 10321853
    Abstract: A method for evaluating positioning of an examination object on a patient-positioning apparatus in a magnetic resonance unit, a magnetic resonance unit, and a computer program product are provided. The method includes acquiring positioning data relating to the examination object using an acquisition unit. Using the acquired positioning data, positioning information relating to the examination object is determined using an analysis unit. Evaluation information is determined using the positioning information, using an evaluation unit. Using the evaluation information, an evaluation signal is transmitted using an output unit. Monitoring of a specific absorption rate may be adjusted using the evaluation signal.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: June 18, 2019
    Assignee: Siemens Healthcare GmbH
    Inventors: Gerhard Brinker, Franz Hebrank, Patrick Sieber
  • NADPH OXIDASE 4 INHIBITORS
    Publication number: 20180179194
    Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.
    Type: Application
    Filed: June 21, 2016
    Publication date: June 28, 2018
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Hamed AISSAOUI, Martin BOLLI, Christoph BOSS, Sylvia RICHARD-BILDSTEIN, Patrick SIEBER
  • Evaluation of the Positioning of an Examination Object
    Publication number: 20170205478
    Abstract: A method for evaluating positioning of an examination object on a patient-positioning apparatus in a magnetic resonance unit, a magnetic resonance unit, and a computer program product are provided. The method includes acquiring positioning data relating to the examination object using an acquisition unit. Using the acquired positioning data, positioning information relating to the examination object is determined using an analysis unit. Evaluation information is determined using the positioning information, using an evaluation unit. Using the evaluation information, an evaluation signal is transmitted using an output unit. Monitoring of a specific absorption rate may be adjusted using the evaluation signal.
    Type: Application
    Filed: January 19, 2017
    Publication date: July 20, 2017
    Inventors: Gerhard Brinker, Franz Hebrank, Patrick Sieber